Targeting Wnts at the Source—New Mechanisms, New Biomarkers, New Drugs
- 1 May 2015
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 14 (5) , 1087-1094
Abstract
Wnt signaling is dysregulated in many cancers and is therefore an attractive therapeutic target. The focus of drug development has recently shifted away from downstream inhibitors of β-catenin. Active inhibitors of Wnt secretion and Wnt/receptor interactions have been developed that are now entering clinical trials. Such agents include inhibitors of Wnt secretion, as well as recombinant proteins that minimize Wnt–Frizzled interactions. These new therapies arrive together with the recent insight that cancer-specific upregulation of Wnt receptors at the cell surface regulates cellular sensitivity to Wnts. Loss-of-function mutations in RNF43 or ZNRF3 and gain-of-function chromosome translocations involving RSPO2 and RSPO3 are surprisingly common and markedly increase Wnt/β-catenin signaling in response to secreted Wnts. These mutations may be predictive biomarkers to select patients responsive to newly developed upstream Wnt inhibitors. Mol Cancer Ther; 14(5); 1087–94. ©2015 AACR.Keywords
This publication has 73 references indexed in Scilit:
- Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cellsNature Communications, 2013
- WNT1 Mutations in Early-Onset Osteoporosis and Osteogenesis ImperfectaNew England Journal of Medicine, 2013
- Recurrent R-spondin fusions in colon cancerNature, 2012
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Wnt/β-Catenin Signaling and DiseaseCell, 2012
- Three decades of Wnts: a personal perspective on how a scientific field developedThe EMBO Journal, 2012
- RNAscopeThe Journal of Molecular Diagnostics, 2012
- Tankyrase inhibition stabilizes axin and antagonizes Wnt signallingNature, 2009
- Small molecule–mediated disruption of Wnt-dependent signaling in tissue regeneration and cancerNature Chemical Biology, 2009
- Frequent epigenetic inactivation of Wnt antagonist genes in breast cancerBritish Journal of Cancer, 2008